Up more 12,000% in a year, but is it really still good value?
This Covid-19 testing specialist has been a major winner from the pandemic. With the shares up over 12,000% in the past 12 months, can they really still be considered good value, as some contend? Our research into the phenomena that is Novacyt reflects on the facts, opportunities and risks.
Novacyt SA (LON:NCTR, PAR:ALNOV) is an international diagnostics group involved in the sale of diagnostic and pathogen testing kits based on molecular and protein testing technologies. We have followed the stock with interest in our regular Coronavirus updates, since February 2020 when we commented on Novacyt’s big break.
Previous article Next article
DON'T MISS OUT!
Get top investment ideas to help safeguard and grow your wealth.
Invaluable insight from the exciting world of smaller companies.
REGISTER FREE
More on Novacyt SA
Impressive results | Trading well | Little to cheer
News covered here includes our assessment of excellent results from a provider of compliance and e-learning…
A refocused business delivers
Having survived a near death experience several years ago, a manufacturer of specialist industrial equipment covered…
